At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
07630 IMPACT THERAP-B
Not Yet Opened 06-02 16:08:45
40.580
-2.020
-4.74%
High42.600
Low38.480
Vol173.80K
Open42.600
D1 Closing42.600
Amplitude9.67%
Mkt Cap11.21B
Tradable Cap11.21B
Total Shares276.17M
T/O6.89M
T/O Rate0.06%
Tradable Shares276.17M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
IMPACT Therapeutics highlights IMP1734 Phase 1/2 data at ASCO 2026; monotherapy ORR 14.3%, paclitaxel combo ORR 24.5%
IMPACT Therapeutics Inc is a China-based company mainly engaged in biotechnology research and commercialization. The Company is in the commercialization stage. The Company is committed to advancing synthetic lethality (SL)-based precision anti-cancer therapies globally. The Company's independently developed core product, senaparib, in China as a 1L maintenance therapy for ovarian cancer (OC). The Company is currently developing product pipeline packages such as PARP1/2, PARP1, ATR, WEE1, PKMYT1/WEE1, DHX9, ATM, USP1, and CHK1/2.